-
Markets
-
Aktien
Sustainable finance2025 Euronext ESG Trends ReportWeiterlesenA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesWeiterlesenThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeWeiterlesenInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondWeiterlesenFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesWeiterlesenTrade mini bond futures on main European government bonds
-
Rohstoffe
- Übersicht
- Kurse überblick
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesWeiterlesenEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameWeiterlesenJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
OCTOPLUS
Identification
Listing sponsor / Agent
FORTIS
Symbol
OCTO
ISIN code
NL0000345718
Trading location
Amsterdam
ICB
Biotechnology
Activity description
The issuer was founded in 1995 and is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on proprietary drug delivery technologies of the company and have fewer side effects, increased patient convenience and better efficacy than existing therapies.
Website address
http://www.octoplus.nl/index.cfm/octoplus
Issuer website
http://www.octoplus.nl/index.cfm/octoplus
Operation
IPO date
Mi. 04/10/2006
IPO type
Introduction by public issue of new shares
IPO type
Initial Public offering
Catégorie
IPO
Operation description
Offering of up to 4,9 million newly issued ordinary shares, at a price range of EUR 4,65 to EUR 5,50 per Share.
Operation calendar
Date of first listing: 4 October 2006 Settlement: 9 october 2006